An outstanding impact including tumor killing and higher tumor regression,
OnCARlytics and Blinatumomab are already a proven commodity preclinically - Rewind to November 2022
See - IMU Announcement (my italics)
8-12 November 2022.Dr. Anthony Park, from Dr. Saul Priceman’s Lab at City of Hope, presented “Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors”.
Key findings of the presentation are as follows;
T-cell activation markers along with IFNγ and IL-2 secretion increase in response to blinatumomab in an onCARlytics dose-dependent manner in co-culture.
Blinatumomab initiates T-cell-mediated tumor killing in onCARlytics infected solid tumor cells.
Blinatumomab treatment following onCARlytics infection and T-cell treatment shows a significantly higher tumor regression compared to onCARlytics, blinatumomab, or T-Cells alone in human tumor
xenograft models of TNBC.
This combination immunotherapy approach shows that blinatumomab can be redirected to
potently target solid tumors with onCARlytics.
The poster is available on Imugene’s website: https://www.imugene.com/conference-presentations.
Imugene CEO/MD Leslie Chong said “Blinatumomab, sold under the brand name Blincyto, is a bispecific T cell engager antibody that targets CD19 and is used to treat a particularly acute form of leukemia. Now combining this with our novel CD19-expressing onCARlytics, we are pleased to see an ability to deliver an outstanding impact including tumor killing and higher tumor regression, which will ideally lead to improved outcomes for cancer sufferers. The results certainly support further development of the combination and program.”
The great thing is Blinatumomab is already approved for intravenous use. Oh and did I mention Amgen (AMGN NASDAQ) owns it..they're only worth a cool $119 USB. Well that's today, maybe they'll be worth a bit more tonight, after the NASDAQ opens.
Opinions Only
